vs
Side-by-side financial comparison of COMMERCE BANCSHARES INC (CBSH) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
COMMERCE BANCSHARES INC is the larger business by last-quarter revenue ($475.7M vs $339.0M, roughly 1.4× HAEMONETICS CORP). COMMERCE BANCSHARES INC runs the higher net margin — 29.8% vs 13.2%, a 16.6% gap on every dollar of revenue. On growth, COMMERCE BANCSHARES INC posted the faster year-over-year revenue change (11.1% vs -2.7%). Over the past eight quarters, COMMERCE BANCSHARES INC's revenue compounded faster (7.1% CAGR vs 0.4%).
Commerce Bancshares, Inc. is a regional bank holding company headquartered in Missouri, with principal offices in Kansas City and St. Louis. It is the corporate parent of Commerce Bank, which offers a diversified line of financial services, including business and personal banking, wealth management and investments through its affiliated companies.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CBSH vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $475.7M | $339.0M |
| Net Profit | $141.6M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | — | 19.9% |
| Net Margin | 29.8% | 13.2% |
| Revenue YoY | 11.1% | -2.7% |
| Net Profit YoY | 10.5% | 19.3% |
| EPS (diluted) | $0.96 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $475.7M | — | ||
| Q4 25 | $449.4M | $339.0M | ||
| Q3 25 | $441.0M | $327.3M | ||
| Q2 25 | $445.8M | $321.4M | ||
| Q1 25 | $428.1M | $330.6M | ||
| Q4 24 | $422.1M | $348.5M | ||
| Q3 24 | $421.4M | $345.5M | ||
| Q2 24 | $414.5M | $336.2M |
| Q1 26 | $141.6M | — | ||
| Q4 25 | $140.7M | $44.7M | ||
| Q3 25 | $141.5M | $38.7M | ||
| Q2 25 | $152.5M | $34.0M | ||
| Q1 25 | $131.6M | $58.0M | ||
| Q4 24 | $136.1M | $37.5M | ||
| Q3 24 | $138.0M | $33.8M | ||
| Q2 24 | $139.6M | $38.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | — | — | ||
| Q4 25 | 40.8% | 19.9% | ||
| Q3 25 | 41.9% | 17.9% | ||
| Q2 25 | 44.0% | 16.8% | ||
| Q1 25 | 39.2% | 21.6% | ||
| Q4 24 | 41.2% | 16.9% | ||
| Q3 24 | 42.4% | 15.0% | ||
| Q2 24 | 43.4% | 11.8% |
| Q1 26 | 29.8% | — | ||
| Q4 25 | 31.3% | 13.2% | ||
| Q3 25 | 32.1% | 11.8% | ||
| Q2 25 | 34.2% | 10.6% | ||
| Q1 25 | 30.7% | 17.5% | ||
| Q4 24 | 32.2% | 10.8% | ||
| Q3 24 | 32.8% | 9.8% | ||
| Q2 24 | 33.7% | 11.4% |
| Q1 26 | $0.96 | — | ||
| Q4 25 | $0.86 | $0.95 | ||
| Q3 25 | $1.06 | $0.81 | ||
| Q2 25 | $1.14 | $0.70 | ||
| Q1 25 | $0.98 | $1.17 | ||
| Q4 24 | $0.83 | $0.74 | ||
| Q3 24 | $1.01 | $0.66 | ||
| Q2 24 | $1.03 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $4.3B | $911.5M |
| Total Assets | $35.7B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $363.4M | ||
| Q3 25 | — | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | — | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | — | $344.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $3.8B | $911.5M | ||
| Q3 25 | $3.8B | $849.2M | ||
| Q2 25 | $3.6B | $882.3M | ||
| Q1 25 | $3.5B | $820.8M | ||
| Q4 24 | $3.3B | $906.9M | ||
| Q3 24 | $3.4B | $878.9M | ||
| Q2 24 | $3.1B | $905.4M |
| Q1 26 | $35.7B | — | ||
| Q4 25 | $32.9B | $2.5B | ||
| Q3 25 | $32.3B | $2.4B | ||
| Q2 25 | $32.3B | $2.5B | ||
| Q1 25 | $32.4B | $2.5B | ||
| Q4 24 | $32.0B | $2.5B | ||
| Q3 24 | $31.5B | $2.5B | ||
| Q2 24 | $30.6B | $2.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $93.6M |
| Free Cash FlowOCF − Capex | — | $87.2M |
| FCF MarginFCF / Revenue | — | 25.7% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $645.1M | $93.6M | ||
| Q3 25 | $129.0M | $111.3M | ||
| Q2 25 | $111.2M | $17.4M | ||
| Q1 25 | $138.6M | $116.6M | ||
| Q4 24 | $577.9M | $43.8M | ||
| Q3 24 | $431.7M | $48.8M | ||
| Q2 24 | $147.4M | $-27.4M |
| Q1 26 | — | — | ||
| Q4 25 | $592.4M | $87.2M | ||
| Q3 25 | $113.3M | $106.3M | ||
| Q2 25 | $100.5M | $13.6M | ||
| Q1 25 | $126.0M | $100.9M | ||
| Q4 24 | $531.7M | $35.2M | ||
| Q3 24 | $419.1M | $39.4M | ||
| Q2 24 | $138.9M | $-33.1M |
| Q1 26 | — | — | ||
| Q4 25 | 131.8% | 25.7% | ||
| Q3 25 | 25.7% | 32.5% | ||
| Q2 25 | 22.5% | 4.2% | ||
| Q1 25 | 29.4% | 30.5% | ||
| Q4 24 | 126.0% | 10.1% | ||
| Q3 24 | 99.5% | 11.4% | ||
| Q2 24 | 33.5% | -9.8% |
| Q1 26 | — | — | ||
| Q4 25 | 11.7% | 1.9% | ||
| Q3 25 | 3.6% | 1.5% | ||
| Q2 25 | 2.4% | 1.2% | ||
| Q1 25 | 2.9% | 4.7% | ||
| Q4 24 | 10.9% | 2.5% | ||
| Q3 24 | 3.0% | 2.7% | ||
| Q2 24 | 2.1% | 1.7% |
| Q1 26 | — | — | ||
| Q4 25 | 4.59× | 2.09× | ||
| Q3 25 | 0.91× | 2.88× | ||
| Q2 25 | 0.73× | 0.51× | ||
| Q1 25 | 1.05× | 2.01× | ||
| Q4 24 | 4.25× | 1.17× | ||
| Q3 24 | 3.13× | 1.44× | ||
| Q2 24 | 1.06× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBSH
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
